EURURO Vol. 73 No. 1

68 148

Genentech/Roche, Novartis, Janssen, Astellas, Celldex, and Acerta; and
grants and consulting fees from Exelixis, Pfizer, Sanofi, Innocrin Pharma,
and BMS. Bernard Escudier has received consulting fees from Bayer,
Pfizer, and Novartis; and honoraria from Bayer, Roche, Pfizer, Genentech,
Novartis, and AVEO. Frede Donskov has received research funding from
Pfizer, Novartis, and GSK. Ahmed Magheli has received financial
compensation for speeches from Janssen, Bayer, Astellas, and Pfizer.
Brigitte Laguerre has received honoraria from Pfizer. Michelle Casey,
Paola Gerletti, Mariajose Lechuga, Xun Lin, and Lucile Serfass are
employees of and own stock in Pfizer. Allan J. Pantuck has received
consulting fees from Pfizer. Michael Staehler has received honoraria,
consulting fees, and research grants from Pfizer, Bayer, GSK, Roche, BMS,
Novartis, Exelixis, and AVEO. Hardev S. Pandha has received honoraria for
advisory work from Ipsen and Esai. Piotr Tomczak, Giacomo Carteni,
Jan Breza, Anup Patel, and Yen-Hwa Chang have nothing to disclose.
Funding/Support and role of the sponsor: These analyses were designed,
funded, and conducted by Pfizer. The S-TRAC study fromwhich data were
collected for these analyses was sponsored by Pfizer. Medical writing
support was provided by Vardit Dror of Engage Scientific Solutions
and was funded by Pfizer Inc. The sponsor played a role in the design and
conduct of the study; data collection, management, and analysis;
and review and approval of the manuscript.
Acknowledgments: Patients treated at the Memorial Sloan Kettering
Cancer Center were supported in part by a Memorial Sloan Kettering
Cancer Center Support Grant/Core Grant (P30 CA008748).
References
[1] National Cancer Institute. SEER cancer statistics factsheets: kidney
and renal pelvis cancer. 2016
[2]
.
[3]
.
[4]
.
[5]
.
[6]
.
[7]
.
[8]
.
[9]
.
[10]
[11]
.
[12]
[13]
[14]
[15]
[16]
[17]
.
[18]
[19]
.
[20]
.
[21]
[22]
E U R O P E A N U R O L O GY 7 3 ( 2 0 18 ) 6 2 – 6 8 68